Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 22, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Achieves High Ranking in Sensitivity Testing Against MERS/SARS Coronaviruses Compared to Other Drugs

PHILADELPHIA, July 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that a new publication abstract in Infectious Disorder Drug Targets (2014 Jul 13. [Epub ahead of print])...
July 14, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma and Bioclones, a Leading South African Biotechnology Company, Join Forces on Novel Therapeutic Cancer Vaccine

PHILADELPHIA, July 14, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced a strategic alliance to develop multiple projects with Bioclones...
July 08, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma and Bioclones Join Forces in Effort to Eradicate HIV/AIDS Virus Based on Recent Clinical Insights of Wistar Institute, University of Pennsylvania

PHILADELPHIA, July 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced execution of an agreement to seek South African government approval...
June 25, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma to Present During the 2014 BIO International Convention June 26

PHILADELPHIA, June 25, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), will present a corporate update on their Advanced Therapies for the Human...
June 16, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate in Middle Eastern Respiratory Syndrome (MERS)

PHILADELPHIA, June 16, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced that a new publication (June 2, 2014) in the Formulary Journal...
June 03, 2014 13:06 ET | Source: AIM ImmunoTech Inc.

Hemispherx Announces That the University of Texas Medical Branch Confirms Activity of Alferon(R) N Against MERS (Middle East Respiratory Syndrome) Virus

PHILADELPHIA, June 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has confirmed that one of its advanced stage biological products, Alferon® N, inhibits...
May 27, 2014 09:26 ET | Source: AIM ImmunoTech Inc.

Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen(R) Formulations

PHILADELPHIA, May 27, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that on May 13, 2014, the United States Patent Office issued U.S....
May 21, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets

PHILADELPHIA, May 21, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced the preliminary stage agreement required to manufacture...
May 14, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Formally Collaborates With the Swiss Department of Defense, Civil Protection and Sports to Study Alferon(R) Against Tamiflu Resistant Influenza Virus Strains

PHILADELPHIA, May 14, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it has entered into a formal collaborative research agreement...
May 09, 2014 16:15 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2014

PHILADELPHIA, May 9, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2014. The net loss (including non-cash effects)...